Sera Prognostics (SERA) Jefferies Global Healthcare Conference 2026 summary

Strategic shift and operational changes

• Redirected investments from clinical research to commercialization following PRIME study results, aiming to accelerate adoption in clinical practice and extend cash runway through 2029.

• Workforce reduction and R&D shift to collaborative projects enabled redeployment of resources to expand field sales, medical presence, and critical commercial functions.

Commercialization and adoption milestones

• Focused on achieving reimbursement and coverage milestones in the next year to drive revenue inflection, with active engagement of Medicaid and commercial payers.

• Adoption efforts target growing numbers of large and medium practices in key states, with staged rollout across 350 providers and ongoing training.

• Engaged in discussions with 13 payers across 15 states, emphasizing NICU cost savings and efficiency to accelerate pilot and coverage decisions.

Clinical evidence and health economics

• PRIME study demonstrated significant reduction in preterm births and NICU admissions, with a number needed to screen of 4.2 to save a NICU day and 40 to prevent a NICU admission, outperforming current standards.

• Sub-analyses on Medicaid and first-time mothers are underway, with early data showing a 20% NICU reduction and substantial cost savings.

• Multiple studies, including AVERT and PRIME, reinforce clinical utility, with ongoing real-world evidence and implementation studies planned.